16/07/2025
The third day of the Regional Forensic Capacity Building for Synthetic Drug Detection and Analysis for South Asia training program resumed with further sessions on Mass Spectrometry led by Mr. Francis Diamond. The content from Modules 03 and 04 continued with a deeper dive into LC/MS and Time of Flight Mass Spectrometry. The session also included the example of the identification of fentanyl analogs.
Later in the day, Dr. Barry Logan presented an insightful session on Novel Psychoactive Substances (NPS): Trends and Challenges, addressing the growing concerns surrounding NPS in the South Asia region. He discussed Public Health Alerts released in collaboration with the Colombo Plan and CFSRE, emphasizing the prevalence of synthetic cannabinoids (CB1 agonists), in South Asia. These substances are often found in herbal products (“Kush”, “Spice”, “K2”), v**e liquids, and adulterated hashish. Examples of commonly detected NPS included AB-FUBINACA, 5F-ADB, MDMB-CHMICA, and JWH-018 (earlier generations). Dr. Logan also highlighted the growing issue of adulterated drugs, noting that many new drugs are being mixed with veterinary drugs and industrial chemicals to extend their effects or increase volume. This trend poses significant public health risks due to the toxicological complications of such adulterants.
Fentanyl analogs, and novel synthetic opioids (e.g. nitazenes, and benzimidazoles) were noted as particularly concerning adulterants appearing in drugs worldwide. A significant seizure of fentanyl itself has been seized in Bangladesh, although currently there are no reports of nitazenes in South Asia, however, that may be a function of testing capability. Dr. Logan also discussed the prevalence of methamphetamine and ketamine in counterfeit M**A or Ecstasy pills. Finally, he discussed the emerging issue of Xylazine (a veterinary sedative), Medetomidine/Dexmedetomidine, and BTMPS, Bis(2,2,6,6-tetramethyl-4-piperidinyl) a chemical light stabilizer being detected as adulterants.
Dr. Logan concluded the day with a presentation on the NPS Discovery Program and its Open Access Drug Early Warning System, showcasing several reports on newly emergent drugs. One notable public alert released in May 2025 concerned the discovery of tetramethylfentanyl-related substances and BTMPS in the drug supply.
To wrap up the day's sessions, Dr. Logan introduced the International Toxic Adulterants Database (ITAD), highlighting the latest version—ITAD 4.0. This database, with data contributed by 42 laboratories across 30 countries, provides valuable information on emerging toxic adulterants. Dr. Logan explained how laboratories could gain access to ITAD and contribute their findings to enhance global awareness and research on toxic adulterants.